Home › Sickle Cell Disease › New York
Sickle Cell Disease clinical trials in New York
21 studies for Sickle Cell Disease are looking for participants at sites in New York.
Cities in New York
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Childrens Hospital at Montefiore, The Bronx
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Sep 28, 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Mount Sinai Hospital, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Columbia University Medical Center_New York_0, New York
- Columbia University Medical Center_New York_0, New York
RecruitingPhase 3
Ages 2 and older · All sexes · Updated Sep 18, 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- NYC Health+Hospitals, Brooklyn
- Interfaith Medical Center, Brooklyn
- Cohen Children's Medical Ctr, Queens
- and 2 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 17, 2026 · NCT06612268A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Icahn School of Medicine at Mount Sinai, New York
- Jacobi Medical Center, The Bronx
RecruitingPhase 2/3
Ages 12 and older · All sexes · Updated Aug 18, 2026 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Western New York BloodCare, Buffalo
- Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center, Hyde Park
- Weill Cornell Medical College - New York Presbyterian Hospital, New York
- and 2 more
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Mount Sinai Medical Center, New York
- Jacobi Medical Center, The Bronx
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Aug 14, 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Jacobi Medical Center, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Richmond University Medical Center- Site Number : 8400038, Staten Island
- Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx
RecruitingPhase 3
Ages 10 to 65 · All sexes · Updated Jul 29, 2026 · NCT06975865Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- New York Medical College, Valhalla
RecruitingPhase 2
6 Months – 21 Years · All sexes · Updated Jul 27, 2026 · NCT02675959Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 to 50 · All sexes · Updated Jul 2, 2026 · NCT04819841131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 12 to 50 · All sexes · Updated Jun 10, 2026 · NCT07015684Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Roswell Park (MRD-HCT), Buffalo
- Columbia Presbytarian (NT-DMT), New York
- Cohen's Children Hospital (NT-DMT), Queens
- and 4 more
RecruitingObservational study
Ages 3 to 20 · All sexes · Updated Jun 4, 2026 · NCT06941389A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre
RecruitingPhase 2
Ages 2 to 50 · All sexes · Updated Jun 3, 2026 · NCT05736419Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York
RecruitingPhase 3
Ages 12 to 35 · All sexes · Updated Mar 23, 2026 · NCT05477563Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Columbia University, New York
RecruitingPhase 2
Ages 2 to 25 · All sexes · Updated Mar 10, 2026 · NCT03587272A Long-term Follow-up Study in Patients Who Received BEAM-101
- Columbia University Irving Medical Center, New York
RecruitingObservational study
Ages 14 to 37 · All sexes · Updated Jan 28, 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Weil Cornell Medical College, New York
- University of Rochester Medical Center, Rochester
Recruiting
Ages 16 to 30 · All sexes · Updated Jan 7, 2026 · NCT06374238Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Mount Sinai Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05519111AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- New York Medical College, Valhalla
RecruitingPhase 2
1 Day – 30 Years · All sexes · Updated Aug 8, 2025 · NCT04099966Cannabidiol in Sickle Cell Disease
- Icahn School of Medicine at Mount Sinai, Manhattan
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT06930703From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.